Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7689385 | 0.84 | ALDH1A1 (0.47) | TACR1TSHRALDH1A1TAAR1 | |
| SCHEMBL754280 | 0.81 | TSHR (0.50) | TACR1TSHRALDH1A1IDO1TAAR1 | |
| SCHEMBL10930321 | 0.78 | TSHR (0.47) | TACR1TSHRALDH1A1IDO1TAAR1 | |
| SCHEMBL10371092 | 0.77 | TSHR (0.54) | TACR1TSHRALDH1A1IDO1TAAR1 | |
| SCHEMBL5575731 | 0.77 | TSHR (0.45) | TACR1TSHRALDH1A1HTR2BTMEM97 | |
| SCHEMBL5555166 | 0.77 | TSHR (0.45) | TACR1TSHRALDH1A1HTR2BTMEM97 | |
| SCHEMBL5423335 | 0.76 | TSHR (0.48) | TACR1TSHRALDH1A1IDO1TAAR1 | |
| SCHEMBL711818 | 0.76 | TSHR (0.48) | TACR1TSHRALDH1A1IDO1TAAR1 | |
| SCHEMBL27620254 | 0.75 | TSHR (0.47) | TACR1TSHRALDH1A1IDO1TAAR1 | |
| SCHEMBL24933884 | 0.73 | TSHR (0.45) | TACR1TSHRALDH1A1IDO1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | UNIVERSITY OF DELAWARE (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | UNIVERSITY OF DELAWARE (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | TST, CYP4F8, CYP4Z1 | TACR1 4246/4885TSHR 1185/4885ALDH1A1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.